[Survey on the Current Advertising and Sales of Mucuna pruriens in Consumer-to-consumer Internet Trading in Japan].

L-3,4-dihydroxyphenylalanine (levodopa) Mucuna pruriens Parkinson’s disease advertisement internet legal

Journal

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
ISSN: 1347-5231
Titre abrégé: Yakugaku Zasshi
Pays: Japan
ID NLM: 0413613

Informations de publication

Date de publication:
01 Dec 2023
Historique:
medline: 5 12 2023
pubmed: 16 10 2023
entrez: 15 10 2023
Statut: ppublish

Résumé

Mucuna pruriens (MP) is leguminous plant which contains 5% of L-3,4-dihydroxyphenylalanine (levodopa) in its seeds. It may have a potential to be used as an alternative therapy for Parkinson's disease (PD). Meanwhile, there is a concern in terms of public health that MP products can be overused by patients with PD. As an entry for patients with PD to acquire MP products in Japan, they are often purchased via internet auctions or free markets. MP products are not reagrded as 'pharmatheutical' by Japanese law as long as the specific legal requirements on advertisements are met, so that the MP products can be advertised or sold without any permission from the authorities. In this study, we aimed to conduct internet survey as to the complianse status of these legal requirements. Several major internet auction or free market websites in Japan were surveyed in May-June 2023 by the authors, and 1157 MP product pages were examined. We found approximately 30-40% of the MP products were suspected to have potential legal risks in terms of their advertisements in their website descriptions, such as claiming pharmatheutical efficacy or describing pharmatheutical-like dosages. In addition, approximately 30-40% of the MP products also did not refer to cautions not to take MP products excessively because of the levodopa ingredients. Current study suggested the need of careful description of the MP products in the auction or free market websites for the MP products exhibitors or sellers, in order to fullfill legal requirements as well as to prevent MP abuse.

Identifiants

pubmed: 37839871
doi: 10.1248/yakushi.23-00145
doi:

Substances chimiques

Levodopa 46627O600J
Plant Extracts 0

Types de publication

English Abstract Journal Article

Langues

jpn

Sous-ensembles de citation

IM

Pagination

1057-1067

Auteurs

Kenichiro Sato (K)

Unit for Early and Exploratory Development, The University of Tokyo Hospital.
Department of Neuropathology, Graduate School of Medicine, The University of Tokyo.

Ayumi Hida (A)

Department of Neurology, Meirikai Tokyo Yamato Hospital.
Daiichi Tokyo Bar Association, Japan.

Yoshiki Niimi (Y)

Unit for Early and Exploratory Development, The University of Tokyo Hospital.

Atsushi Iwata (A)

Department of Neurology, Tokyo Metropolitan Geriatric Hospital.

Takeshi Iwatsubo (T)

Unit for Early and Exploratory Development, The University of Tokyo Hospital.
Department of Neuropathology, Graduate School of Medicine, The University of Tokyo.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH